Med-El Corporation
29
4
5
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
17.2%
5 terminated/withdrawn out of 29 trials
73.7%
-12.8% vs industry average
0%
0 trials in Phase 3/4
100%
14 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (29)
MED-EL Remote Care Multi-Center Feasibility Study
Role: lead
Comparison of Performance Using MED-EL Automatic Sound Management
Role: lead
Impact of Anatomy-Based Cochlear Implant Programming on Early Performance
Role: lead
Benefits of Bimodal Streaming With MED-EL Cochlear Implants and Starkey Hearing Aids
Role: lead
Design Improvements With SONNET 3
Role: lead
Maintaining Cochlear Patency After VIIIth Nerve Surgery
Role: collaborator
Innsbruck Health Promotion Program
Role: collaborator
Single-Sided Deafness in the Medicare Population
Role: lead
Single-Sided Deafness and Asymmetric Hearing Loss
Role: lead
Expanded Indications in the Pediatric BONEBRIDGE Population
Role: lead
SPI-1005 in Adults Receiving Cochlear Implant
Role: collaborator
Expanded Indications in the Adult Cochlear Implant Population
Role: lead
Cochlear Implants in Young Children With SSD
Role: collaborator
Expanded Indications in the MED-EL Pediatric Cochlear Implant Population
Role: lead
Outcomes in Children With Pre-operative Residual Hearing
Role: collaborator
BONEBRIDGE Bone Conduction Implant in Adults
Role: lead
Anatomy Based Selection of CI Array for SSD Patients
Role: collaborator
Adhear Bone Conduction System
Role: collaborator
Cochlear Implantation in Cases of Single-Sided Deafness
Role: collaborator
Reverberation Effects on MED-EL Recipients
Role: collaborator